Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry

mAbs

Volumn 5, Issue 5, 2013, Pages 621-623

  Beck, Alain ^a   Reichert, Janice M ^b  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Reichert Biotechnology Consulting LLC   (United States)

Author keywords

Adalimumab; Antibody; Bevacizumab; Biobetters; Biosimilars; Cetuximab; Etanercept; Fc fusion protein; Follow on biologicals; Infliximab; Mass spectrometry; Rituximab; Trastuzumab

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; BIOSIMILAR AGENT; CETUXIMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TRASTUZUMAB;

AMINO ACID SEQUENCE; DRUG APPROVAL; DRUG INDUSTRY; DRUG SAFETY; EUROPE; HUMAN; NONHUMAN; REVIEW;

ADALIMUMAB; ANTIBODY; BEVACIZUMAB; BIOBETTERS; BIOSIMILARS; CETUXIMAB; ETANERCEPT; FC-FUSION PROTEIN; FOLLOW-ON BIOLOGICALS; INFLIXIMAB; MASS SPECTROMETRY; RITUXIMAB; TRASTUZUMAB;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUG INDUSTRY; EUROPE; EUROPEAN UNION; HUMANS;

EID: 84883880492     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25864     Document Type: Review

References (33)

1. Beck A, Carter PJ, Gerber HP, Lugovskoy AA, Wurch T, Junutula JR, et al. 8th Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. MAbs 2013; 5:339-57; http://dx.doi. org/10.4161/mabs.24105
2. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, et al. Biosimilars-why terminology matters. Nat Biotechnol 2011; 29:690-3; PMID:21822237; http://dx.doi.org/10.1038/nbt.1936
3. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013; PMID:23649935; http://dx.doi.org/10.1007/s40259-013-0036-3
4. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747
5. Beck A. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 2011; 3:107-10; PMID:21285536; http://dx.doi.org/10.4161/mabs.3.2.14785
6. Beck A. Glycosylation Engineering of Biopharmaceuticals. Methods in Molecular Biology, Vol. 988. Beck, Alain (Ed.) Springer, 2013.
7. Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637-46; PMID:22510259; http://dx.doi. org/10.1021/ac3002885
8. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985-90; PMID:18779806; http://dx.doi.org/10.1038/nbt0908-985
9. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood 2012; 120:5111-7; PMID:23093622; http://dx.doi.org/10.1182/blood-2012-04-425744
10. Reichert JM, Beck A, Iyer H. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK. MAbs 2009; 1:394-416; PMID:20065643; http://dx.doi.org/10.4161/mabs.1.5.9630
11. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011; 3:415-6; PMID:21785279; http://dx.doi. org/10.4161/mabs.3.5.17334
12. Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin JH, Weise M, et al. Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 2012; 30:1179-85; PMID:23222783; http://dx.doi. org/10.1038/nbt.2447
13. Scientific considerations in demonstrating biosimilarity to a reference product [Internet]. Washington (DC); US Food and Drug Administration: c2012 [cited 23 July 2013]. Available from: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
14. Quality considerations in demonstrating biosimilarity to a reference protein product [Internet]. Washington (DC); US Food and Drug Administration: c2012. [cited 23 July 2013]. Available from: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf
15. Kálmán-Szekeres Z, Olajos M, Ganzler K. Analytical aspects of biosimilarity issues of protein drugs. J Pharm Biomed Anal 2012; 69:185-95; PMID:22633839; http://dx.doi.org/10.1016/j.jpba.2012.04.037
16. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2012; 11:527-40; PMID:22743980; http://dx.doi.org/10.1038/nrd3746
17. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier- Cianférani S. Characterization of therapeutic antibodies and related products. Anal Chem 2013; 85:715-36; PMID:23134362; http://dx.doi. org/10.1021/ac3032355
18. Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010; 2:379-94; PMID:20458189
19. Gahoual R, Burr A, Busnel JM, Kuhn L, Hammann P, Beck A, et al. Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry. MAbs 2013; 5:479-90; PMID:23563524; http://dx.doi.org/10.4161/mabs.23995
20. Chen SL, Wu SL, Huang LJ, Huang JB, Chen SH. A global comparability approach for biosimilar monoclonal antibodies using LC-tandem MS based proteomics. J Pharm Biomed Anal 2013; 80:126-35; PMID:23563225; http://dx.doi.org/10.1016/j. jpba.2013.02.040
21. Tan Q, Guo Q, Fang C, Wang C, Li B, Wang H, et al. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. MAbs 2012; 4:761-74; PMID:23032066; http://dx.doi.org/10.4161/mabs.22276
22. Beck A, Diemer H, Ayoub D, Debaene F, Wagner-Rousset E, Carapito C, et al. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. Trends Analyt Chem 2013; 48:81-95; http://dx.doi. org/10.1016/j.trac.2013.02. 014
23. Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, et al. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottomup ESI and MALDI mass spectrometry techniques. MAbs 2013; 5:699-710; http://dx.doi.org/10.4161/mabs. 25423
24. Cheraghali AM. Current status of biopharmaceuticals in Iran's pharmaceutical market. GaBI J 2013; 2:26-9; http://dx.doi.org/10.5639/gabij. 2013.0201.008
25. McCamish M, Woollett G. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther 2013; 93:315-7; PMID:23443756; http://dx.doi. org/10.1038/clpt.2013.17
26. Damen CW, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, et al. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom 2009; 20:2021-33; PMID:19744865; http://dx.doi. org/10.1016/j.jasms.2009.07.017
27. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-2; PMID:21478841; http://dx.doi. org/10.1038/nbt.1839
28. Sundaram S, Matathia A, Qian J, Zhang J, Hsieh MC, Liu T, et al. An innovative approach for the characterization of the isoforms of a monoclonal antibody product. MAbs 2011; 3:505-12; PMID:22123057; http://dx.doi.org/10.4161/ mabs.3.6.18090
29. Janin-Bussat MC, Tonini L, Huillet C, Colas O, Klinguer-Hamour C, Corvaïa N, et al. Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry. Methods Mol Biol 2013; 988:93-113; PMID:23475716; http://dx.doi. org/10.1007/978-1-62703-327-5-7
30. Toyama A, Nakagawa H, Matsuda K, Sato TA, Nakamura Y, Ueda K. Quantitative structural characterization of local N-glycan microheterogeneity in therapeutic antibodies by energy-resolved oxonium ion monitoring. Anal Chem 2012; 84:9655-62; PMID:23004563; http://dx.doi.org/10.1021/ac3023372
31. McCamish M, Woollett G. The rise of the biosimilar. Expert Rev Clin Pharmacol 2012; 5:597-9; PMID:23234317; http://dx.doi.org/10.1586/ecp.12.60
32. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012; 91:405-17; PMID:22318617; http://dx.doi. org/10.1038/clpt.2011.343
33. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011; 3:209-17; PMID:21441787; http://dx.doi.org/10.4161/mabs.3.2.15005